CA-GLOBALPLATFORM
24.5.2023 08:01:30 CEST | Business Wire | Press release
GlobalPlatform, a leading digital standards organization, has launched a broad-reaching initiative to drive engagement across security experts in the full automotive value chain and adjacent digital services. As a leader in delivering specifications and certifications for secure digital services — over 70 billion GlobalPlatform secure components deployed worldwide —GlobalPlatform is now addressing emerging automotive regulations such as new vehicle type approvals and the shift towards vehicles as a service. GlobalPlatform’s automotive initiative will optimize and accelerate the deployment of secure components, trusted digital architecture, security APIs, and security lifecycle management within the automotive sector. This initiative is being led by a dedicated Automotive Task Force to foster the alignment of GlobalPlatform technologies with automotive use cases. GlobalPlatform has also partnered with automotive standards organizations and formed the Cybersecurity Vehicle Forum to unite the automotive ecosystem in optimizing cybersecurity for vehicles.
“Recent automotive cybersecurity regulations and emerging trends like the move towards autonomous driving and flexible mobility solutions are requiring car manufacturers to become more agile and adaptable in the deployment of secure vehicle services. GlobalPlatform’s secure component technologies support the automotive sector’s compliance with these new regulations and requirements,” said Ana Tavares Lattibeaudiere, Executive Director, GlobalPlatform.
In addition to launching the Automotive Task Force, GlobalPlatform established a cooperative agreement with the Society of Automotive Engineers (SAE) to work on the harmonization of hardware-based secure execution environments in automotive. GlobalPlatform has also partnered with AUTOSAR to coordinate the alignment of secure component standards and specifications for automotive. Furthermore, GlobalPlatform has joined the Auto-ISAC community and has an active memorandum of understanding (MoU) with the Car Connectivity Consortium. These alliances will ensure coordination and alignment on common requirements with key automotive and cybersecurity organizations.
“GlobalPlatform is committed to working with the full automotive value chain to address current automotive security requirements while also focusing on developing interoperable, secure components to meet emerging vehicle standards,” said Gil Bernabeu, Chief Technology Officer, GlobalPlatform.
Another key aspect of GlobalPlatform’s automotive initiative is the launch of the Cybersecurity Vehicle Forum, which will strengthen engagement and cooperation between GlobalPlatform members and the wider automotive ecosystem. The Forum plays an invaluable role in identifying and prioritizing automotive industry requirements to deliver secure component services that span the lifecycle of a vehicle. With global events planned throughout the year, the Cybersecurity Vehicle Forum gives car manufacturers, component companies, automotive regulators, and others a platform to explore the current and future automotive use cases for trusted services and hardware-based secure services.
GlobalPlatform welcomes existing and new member contributions in developing the next generation of automotive security standards and invites the automotive ecosystem to participate in the Cybersecurity Vehicle Forum.
Contact automotive@globalplatform.org to learn more.
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices, which deliver end-to-end security, privacy, simplicity, and convenience to users. It achieves this by providing standardized technologies and certifications that empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom